Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
abbv-6628
- Development stage
- Phase 2
- Lead developer
- AbbVie
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravitreal
01
Overview
ABBV-6628 is an investigational monoclonal antibody fragment being developed by AbbVie for the treatment of *geographic atrophy (GA) secondary to age-related macular degeneration (AMD)*. It is administered by **intravitreal injection**, targeting pathological processes in GA likely via immunological or molecular mechanisms, although its specific molecular target has not been disclosed in available public sources. The drug is evaluated primarily for safety, pharmacokinetics, and preliminary efficacy in clinical trials involving adults over 50 years old with GA. The trial involves staged cohorts receiving ABBV-6628 or SYFOVRE (pegcetacoplan), with a focus on visual function, adverse events, ocular imaging, and laboratory measures[6].
- Brand names
- ABBV-6628ABBV6628ABBV 6628
- Other names
- ABBV-6628ABBV6628ABBV 6628
02
Targets
C5
Beyond the preview
Go deeper on abbv-6628.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on abbv-6628.